๐ Adverse Drug Effects (ADEs): Types, Examples, and Why Pharmacovigilance Matters
By Dr. Sk Sabir Rahaman, MBBS, MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD
๐ What Are Adverse Drug Effects (ADEs)?
Medicines save lives — but they can also cause harm. Not all harmful effects are due to “wrong drugs” or “overdose.” Even when used correctly, drugs can produce undesirable, harmful effects known as Adverse Drug Effects (ADEs).
๐ Let’s clarify a few important terms:
-
Adverse Drug Effect (ADE): Any undesirable, harmful effect of a drug during its normal clinical use.
-
Adverse Drug Reaction (ADR) [WHO]: A noxious and unintended response to a drug at normal doses used in humans for prevention, diagnosis, or therapy.
-
Adverse Event (AE): Any medical occurrence during drug therapy — may or may not be caused by the drug.
⚖️ Complete Classification of ADRs (Types A–F)
| Type | Name | Nature | Predictable? | Dose-Dependent? | Examples |
|---|---|---|---|---|---|
| A | Augmented | Exaggerated pharmacologic action | Yes | Yes | Bleeding with warfarin, hypoglycemia with insulin |
| B | Bizarre | Idiosyncratic / allergic | No | No | Anaphylaxis to penicillin, SJS with sulfonamides |
| C | Chronic | Due to prolonged use | Often | Sometimes | Corticosteroids → osteoporosis |
| D | Delayed | Appear long after exposure | Often not | Sometimes | Thalidomide teratogenicity, carcinogenicity with estrogens |
| E | End-of-use | Withdrawal effects | Yes | No | Opioid withdrawal, rebound HTN with clonidine |
| F | Failure of therapy | Ineffectiveness | Often | Yes | Antibiotic resistance, OCP failure with rifampin |
๐ Detailed Insights
1. Type A (Augmented) – “Dose-Related”
-
Predictable, common.
-
Managed by dose reduction.
-
Examples: Hypotension with antihypertensives, dry mouth with atropine.
2. Type B (Bizarre) – “Unpredictable”
-
Immune-mediated or genetic.
-
Examples:
-
Type I allergy (IgE): Anaphylaxis with penicillin.
-
Idiosyncrasy: G6PD deficiency → hemolysis with primaquine.
-
3. Type C (Chronic)
-
From long-term therapy.
-
Examples: Cushingoid features with corticosteroids, pulmonary fibrosis with amiodarone.
4. Type D (Delayed)
-
Effects appear after months/years.
-
Examples: Vaginal cancer due to DES, secondary cancers with alkylating agents.
5. Type E (End-of-use / Withdrawal)
-
Sudden stopping → rebound effects.
-
Examples: Rebound HTN after clonidine withdrawal, adrenal crisis after abrupt steroid withdrawal.
6. Type F (Failure of Therapy)
-
Drug fails to work as intended.
-
Example: OCP failure with rifampin (due to enzyme induction).
๐งฌ Immunological ADRs (Gell & Coombs Classification)
-
Type I (Immediate / Anaphylactic): IgE mediated; rapid onset → urticaria, anaphylaxis.
-
Type II (Cytotoxic): IgG/IgM antibodies attack cells → Hemolytic anemia with quinidine.
-
Type III (Immune Complex): Ag-Ab deposition → Serum sickness, SJS.
-
Type IV (Delayed, T-cell mediated): Contact dermatitis from topical drugs.
⚠️ Other Important ADR-Related Concepts
✅ Idiosyncrasy
-
Genetically determined abnormal reaction.
-
Example: Aplastic anemia with chloramphenicol.
✅ Drug Dependence
-
Psychological: Craving for euphoria.
-
Physical: Withdrawal symptoms on stopping.
-
Example: Opioids, benzodiazepines.
✅ Iatrogenic Diseases
-
Physician/therapy-induced.
-
Example: Drug-induced Parkinsonism (metoclopramide).
✅ Teratogenicity
-
Malformations due to exposure in pregnancy (highest risk: weeks 2–8).
-
Examples:
-
Thalidomide → limb deformities
-
Tetracyclines → discolored teeth
-
Antithyroid drugs → fetal goiter
-
✅ Carcinogenicity / Mutagenicity
-
Example: Estrogens (carcinogenic), Alkylating agents (mutagenic).
✅ Photosensitivity
-
Phototoxic: Doxycycline, fluoroquinolones
-
Photoallergic: Sulfonamides
✅ Organ-Specific Toxicities
| Organ | Common Drugs |
|---|---|
| Liver | INH, rifampicin, paracetamol |
| Kidney | Aminoglycosides, cisplatin, amphotericin B |
| Ear | Aminoglycosides, loop diuretics |
| Eye | Ethambutol, chloroquine |
๐ฉบ Pharmacovigilance: Guarding Drug Safety
Definition (WHO): The science of detecting, assessing, understanding, and preventing adverse drug effects.
-
Objectives: Improve patient safety, ensure rational drug use, support regulatory action.
-
Causality Assessment Tools: Naranjo’s Algorithm, WHO-UMC Scale.
⚠️ Need for ADR Reporting in India:
India has one of the largest, most genetically diverse populations in the world. With widespread use of generic medicines, traditional remedies, and polypharmacy for communicable and non-communicable diseases, the risk of adverse drug reactions (ADRs) is significant.
Yet, ADRs are often underreported due to:
-
Lack of awareness among healthcare providers
-
Fear of blame or legal consequences
-
Inadequate reporting systems
๐ Improving ADR reporting is essential to safeguard patients, improve prescribing practices, and guide regulatory actions.
๐ฉ⚕️ Who Can Report ADRs?
ADR reporting is not limited to doctors. It is a shared responsibility:
-
Healthcare professionals – doctors, dentists, pharmacists, nurses
-
Patients and consumers – direct reporting is encouraged
-
Pharmaceutical companies – mandatory by regulation
๐ฌ Methods of Reporting ADRs in India
Several convenient channels exist to encourage reporting:
-
Spontaneous reporting (most common)
-
Electronic reporting via mobile apps and email
-
ADR forms available at ADR Monitoring Centres (AMCs)
๐ฎ๐ณ Pharmacovigilance Programme of India (PvPI)
Background
-
Launched: July 2010 by Ministry of Health & Family Welfare (MoHFW)
-
Implemented by: Indian Pharmacopoeia Commission (IPC), Ghaziabad (as the National Coordination Centre, NCC)
-
Aim: Monitor drug safety and promote rational medicine use
Objectives
-
Establish a nationwide patient safety reporting system
-
Detect and analyze new safety signals
-
Share safety information with stakeholders
-
Integrate pharmacovigilance into public health programmes and hospitals
Structure
-
National Coordination Centre (NCC): IPC, Ghaziabad
-
Zonal/Regional Centres: Mentor ADR Monitoring Centres
-
ADR Monitoring Centres (AMCs): 600+ across India (medical colleges, hospitals)
-
Global Link: India contributes ADR data to WHO-Uppsala Monitoring Centre’s VigiBase (VigiFlow)
๐ ️ ADR Reporting Tools under PvPI
-
Suspected ADR Reporting Forms (for both healthcare professionals & patients)
-
PvPI Mobile App for quick online reporting
-
Toll-free helpline: 1800-180-3024
-
Email: pvpi@ipc.gov.in
๐ Major Achievements of PvPI
-
Collected over 500,000 ADR reports in VigiFlow
-
Detected new safety signals → regulatory actions (label changes, warnings)
-
Conducted training and capacity-building workshops nationwide
-
Collaborated with CDSCO (Central Drugs Standard Control Organization) for regulatory decisions
๐ง Challenges in ADR Reporting
Despite progress, several hurdles remain:
-
Underreporting due to low awareness and motivation
-
Minimal pharmacovigilance training at the undergraduate level
-
Workload of healthcare professionals limiting reporting time
-
Limited patient awareness about their right to report ADRs
✅ The Way Forward
To strengthen India’s ADR reporting system:
-
Expand AMCs to private and peripheral hospitals
-
Incorporate pharmacovigilance education in medical, pharmacy, and nursing curricula
-
Encourage patient reporting through simplified mobile apps & awareness campaigns
-
Provide continuous training for healthcare professionals
๐ Visit My Website for Articles & other Free PDFs and Resources
Comments
Post a Comment